Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney.
Kankatsu YunAdrian MolenaarApril FiedlerAnna-Theresa MarkM. R. EcclesD. M. O. BecroftAnthony E. Reeve
22
Citation
0
Reference
10
Related Paper
Citation Trend
Keywords:
Blastema
Northern blot
Topics:
Cite
Blastema
Northern blot
Cite
Citations (22)
Immunoreactive insulin-like growth factor I (IGF-I) has recently been demonstrated in multiple tissues, including liver, kidney, lung, testes, and brain. Tissue IGF-I levels in hypophysectomized rats are elevated by GH. To examine whether tissue IGF-I production is regulated by local as well as systemic influences, we studied rat kidney IGF-I gene expression in renal compensatory hypertrophy occurring after unilateral nephrectomy. Northern analysis of kidney poly(A) RNA probed with [32P]IGF-I mouse cDNA revealed the presence of a mRNA species 1.3 kilobases in size. Dot hybridization of kidney poly(A) RNA showed that IGF-I mRNA was induced 5- to 6-fold in the kidneys of nephrectomized animals relative to levels in control sham-operated rats. This induction was present 24 h after surgery and continued for at least 7 days after the operation. Kidney radioimmunoassayable IGF-I content was also increased 73% in nephrectomized animals, although this was only apparent on the fourth day after surgery. In contrast, liver IGF-I mRNA levels were comparable in both experimental and control animals, suggesting that the IGF-I induction was specific to the tissue undergoing compensatory growth. Serum IGF-I and GH levels were not altered in nephrectomized and control animals for the duration of the experiments. These studies, therefore, confirm that IGF-I is synthesized in the kidney, and that kidneys undergoing compensatory growth have increased levels of IGF-I mRNA. This phenomenon occurs independently of changes in GH secretion, indicating that paracrine or autocrine factors are involved in the control of renal IGF-I production. (Endocrinology120: 718–724, 1987)
Compensatory growth (organ)
Somatomedin
Renal Hypertrophy
Cite
Citations (140)
Cite
Citations (18)
Plasma corticosteroid-binding globulin (CBG) is produced by the liver, but low levels of CBG mRNA have been detected in other tissues, including the kidney. Glucocorticoids influence postnatal renal development in rodents, and CBG production in the kidney may influence the local bioavailability of glucocorticoids. We, therefore, used in situ hybridization and immunohistochemistry to define the sites of CBG biosynthesis during postnatal development and have found that the liver and kidney are major sites of CBG biosynthesis in the first weeks of life. Both CBG and its mRNA were undetectable in the neonatal liver, and only a weak hybridization signal for CBG mRNA was present in the 7-day-old mouse liver. In neonatal mice, the developing tubules of the kidney represent the most active site of CBG biosynthesis, and immunoreactive CBG was also detected in the same cells. By 7 days of age, CBG and its mRNA were colocalized to the proximal convoluted tubules of the juxtamedullary nephrons. The abundance of CBG mRNA in the liver increased from 10 days of age and was accompanied by similar increases in serum CBG until adult levels were reached by 4 weeks of age. In contrast, CBG mRNA in the kidney increased to a maximum during the third week of life, but was undetectable 3 weeks later. The CBG within the proximal convoluted tubules was located in secretory granules close to the luminal surface of the epithelial cells, suggesting that it is secreted into the tubular lumen. Western analysis revealed that marked proteolytic degradation of CBG occurs in the urine concurrently with an increase in CBG biosynthesis in the developing kidney. Thus, the liver is not the only site of CBG biosynthesis in the developing mouse, and CBG production by the epithelial cells of the proximal convoluted tubules may influence glucocorticoid-dependent maturation of the kidney tubules by a process that somehow involves proteolytic degradation.
Transcortin
Cite
Citations (52)
We studied the effect of thyroxine on alcohol dehydrogenase activity, immunoreactive protein levels and messenger RNA levels in the livers of thyroidectomized and sham-operated male rats. Effects on kidney alcohol dehydrogenase activity were also examined. Shamoperated rats injected with 100 μg thyroxine/kg/day, which induced hyperthyroidism, showed a 30% decrease in liver and a 40% decrease in kidney alcohol dehydrogenase activity compared with sham-operated rats injected with vehicle. Hypothyroid rats exhibited a 1.5-fold increase in alcohol dehydrogenase activity in liver and kidney compared with thyroidectomized rats injected with a replacement dose of 20 μg thyroxine/kg/day. We saw a twofold and a 2.5-fold higher level of alcohol dehydrogenase activity in liver and kidney, respectively, of hypothyroid rats compared with hyperthyroid rats. These effects were not accounted for by nutritional differences; daily food intake did not differ between groups. Immunoreactive protein levels as seen on Western blots varied in the same direction as enzyme activity. Northern-blot analysis showed higher levels of liver alcohol dehydrogenase messenger RNA in hypothyroid rats compared with euthyroid rats. These studies show that liver alcohol dehydrogenase activity and protein levels are modulated by thyroxine at pathophysiologically relevant levels and that this effect is not due to changes in food intake; kidney alcohol dehydrogenase activity is regulated in parallel. The change in alcohol dehydrogenase activity appears to be controlled in part by pretranslational mechanisms in hypothyroid animals and by posttranslational mechanisms in hyperthyroid animals. (Hepatology 1993;17:701-706.)
Cite
Citations (5)
Recent studies have shown that the renal synthesis of insulin-like growth factor binding proteins (IGFBPs) is altered in insulin-deficient diabetes mellitus, suggesting that these changes may be implicated in the alterations in renal function and morphology that accompany diabetes. To investigate the time course and the precise cellular distribution of changes in IGFBP expression, we used quantitative in situ hybridization to analyze renal IGF-I and IGFBP-1 to -5 messenger RNA (mRNA) localization and levels from 2 days to 6 months after the onset of streptozotocin-induced diabetes. There was an immediate sharp decline in IGF-I mRNA levels in the outer medulla that persisted for up to 3 months and a much smaller reduction in IGF-I mRNA levels in the medullary thick ascending limbs (MTALs). In nondiabetic animals, IGFBP-1 mRNA is most abundant in the MTALs. Immediately after the induction of diabetes, however, there was a greater than 2-fold increase in cortical IGFBP-1 mRNA and a 75% decrease in IGFBP-1 mRNA in MTALs. These changes persisted for up to 6 months in the diabetic animals. In contrast, IGFBP-5 mRNA levels were increased in the outer medulla and decreased in the cortex of diabetic kidneys. No significant changes in renal IG-FBP-2 mRNA levels or distribution were noted, and changes in IG-FBP-3 and -4 mRNA levels were subtle. In summary, streptozotocin-induced diabetes is associated with very prominent and complex alterations in renal IGF system gene expression, including robust increases in cortical IGFBP-1 and profound decreases in cortical IG-FBP-5 mRNA and medullary IGF-I mRNA levels. The divergent changes in IGFBP-1 and -5 mRNA levels in cortex vs. outer medulla indicate that regulation of IGFBP mRNA levels is quite complex.
Renal cortex
Renal medulla
Cite
Citations (78)
Insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) is generally believed to inhibit IGF action in the circulation. In contrast, IGFBP-1 has been reported to interact with cell surfaces and enhance IGF-I action locally in some tissues. Renal IGFBP-1 levels are found elevated in various conditions characterized by renal growth (e.g. diabetes mellitus, hypokalemia). To test whether IGFBP-1 is a renotropic factor, IGFBP-1 was administered alone or in combination with IGF-I to Snell dwarf mice, an in vivo model without compensatory feedback effects on growth hormone (GH) secretion. In three control groups of Snell dwarf mice, placebo, GH or IGF-I was administered. Compared with placebo, kidney weight increased in all treated groups, however, with different effects on kidney morphology. Administration of IGF-I, alone or in combination with IGFBP-1, tended to increase glomerular volume, while no changes were seen in the other groups. Administration of IGFBP-1 or IGFBP-1+IGF-I both caused dilatation of the thin limbs of Henle's loop, while GH or IGF-I administration had no visible effect. Furthermore, IGF-I administration resulted in an increased mean number of nuclei per cortical area and renal weight, whereas GH, IGF-I+IGFBP-1 or IGFBP-1 caused a decreased renal nuclei number. In situ hybridization and immunohistochemistry showed specific changes of the renal IGF system expression patterns in the different groups. Particularly, IGFBP-1 administration resulted in extensive changes in the mRNA expression of the renal IGF system, whereas the other administration regimen resulted in less prominent modifications. In contrast, administration of IGFBP-1 and IGFBP-1+IGF-I resulted in identical changes in the protein expression of the renal IGF system. Our results indicate that IGFBP-1, alone or in combination with IGF-I, demonstrated effects on the renal tubular system that differ from the effects of IGF-I.
Somatomedin
Cite
Citations (6)
Cite
Citations (0)
Resistance to the action of PTH is encountered in chronic renal failure (CRF). This was attributed to downregulation of PTH receptor due to the state of secondary hyperparathyroidism of CRF. The present study examined whether the amount of PTH-PTH-related peptide (PTH-PTHrP) mRNA in a traditional (kidney) and a nontraditional (liver) organs for PTH action was reduced in CRF. PTH-PTHrP mRNA was measured in kidney and liver obtained from normal rats, animals with CRF of 6 weeks’ duration, normocalcemic parathyroidectomized CFR rats and from CRF and normal rats treated with verapamil. The mRNA of receptor was quantitated with Northern blot analysis of kidney RNA and liver poly A+ RNA. The relative amounts of mRNA of the PTH-PTHrP receptor to that of β-actin in both kidney and liver of CRF rats were significantly (p < 0.01) lower than in normal animals. Parathyroidec-tomy of CRF rats was followed either by significant (p < 0.01) improvement (kidney) or normalization (liver) of the receptor mRNA. Treatment of CRF rats with verapamil also significantly (p < 0.01) improved the concentration of the receptor mRNA in the kidney. The data demonstrate that CRF is associated with downregulation of the PTH-PTHrP receptor mRNA in kidney and liver. This defect is partially or completely reversed by parathyroidectomy of the CRF rats or their treatment with verapamil. The decrease in the receptor mRNA would likely result in a decrease in PTH receptor synthesis and consequently PTH receptor numbers, and hence relative resistance to the action of PTH. It is proposed that, at least, one signal that mediates the reduction in the amount of the receptor mRNA is the PTH-induced rise in cytosolic calcium in CRF. Indeed, both parathyroidectomy of CRF rats or their treatment with verapamil is associated with normalization of cytosolic calcium and significant improvement in the expression of the receptor mRNA.
Northern blot
Cite
Citations (59)
Increased growth hormone-releasing factor messenger ribonucleic acid (GRF mRNA) and decreased somatostatin (SRIF) mRNA levels have been reported in the hypothalamus of hypophysectomized rats as well as of dwarf mice. In order to elucidate the effect of the growth hormone-insulin-like growth factor I (GH-IGF-I) axis on hypothalamic GRF and SRIF synthesis, we measured levels of mRNA coding for GRF and SRIF and for pituitary GH in pubertal male rats treated for 3 weeks with antirat GRF γ-globulin (GRF-ab), anti-SRIF γ-globulin (SRIF-ab) or both. Immunoneutralization of circulating endogenous GRF resulted in a marked decrease in serum IGF-I and pituitary GH mRNA levels in Northern blot analysis, whereas it caused a significant increase in GRF mRNA levels in the arcuate nucleus as assessed by both Northern blot and in situ hybridization analysis. SRIF mRNA levels in the periventricular nucleus were slightly decreased by GRF-ab treatment when analyzed by in situ hybridization, but not significantly after Northern blot analysis. Immunoneutralization of circulating endogenous SRIF failed to affect mRNA levels of hypothalamic GRF and SRIF but caused a slight reduction in pituitary GH mRNA levels. Levels of mRNA coding for hypothalamic GRF and pituitary GH were also measured by Northern blot analysis in young male rats treated with rat GRF-ab for 2 weeks and replaced with rat GH or IGF-I for the second 1 week. Replacement with either rat GH or IGF-I suppressed the increased hypothalamic GRF mRNA levels. These data indicate that endogenous GRF is essential for normal synthesis of pituitary GH and that both GH and IGF-I negatively regulate the synthesis of hypothalamic GRF.
Northern blot
Cite
Citations (22)